Skip to main content
TipRanks
Go Ultimate75% OFF

Cellectis SA (ZVA) Q3 2026 Earnings Report

0 Followers

DE:ZVA Q3 2026 EPS Results

Actual EPS
-EUR 0.55
Consensus EPS
-EUR 0.16
Beat/Miss
Missed by -EUR 0.40
One Year Ago EPS
EUR 0.01

DE:ZVA Q3 2026 Revenue Results

Actual Revenue
EUR 3.27M
Expected Revenue
EUR 13.51M
Beat/Miss
Missed by -EUR 10.23M
YoY Revenue Growth
-89.13%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/13/2026
Time
Before Open
Conference Call
Friday, November 13, 2026
DE:ZVA Upcoming Earnings

Cellectis SA's next earnings date is estimated for March 4, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:ZVA Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 13, 2026|% Change Since:-25.81%|
Earnings Call Sentiment|Positive

The call was strategically optimistic, centered on the transition to in vivo gene editing and encouraging preclinical results for HEAL-101 and HEAL-201. The company reiterated clinical timelines, described its LNP safety and prior clinical experience favorably, and expects cash runway into the second half of 2028. These positives were offset by the discontinuation of legacy cell therapy programs, planned headcount reductions, a substantial decline in revenue, lower cash and financial assets, and restructuring-related expenses. Overall, the number and strength of the stated pipeline and financing highlights outweighed the challenges.

Company Guidance

Cellectis said the investigator-initiated trial for HEAL-101 in China is on track, with preliminary clinical data expected in the second half of 2027; dose escalation is expected to start in Q1, the starting dose is anticipated to be effective, and by the end of year the company expects to start seeing the nine-month type of durability of effect. HEAL-201 is planned to enter phase I, with preliminary clinical data expected in the first half of 2028, while LDL-C reduction data will be provided in June. The company currently expects global headcount to be reduced by up to 70% from its pre-transition level over the course of 2026 and 2027, and expects to have a cash runway into the second half of 2028. Management expects HEAL-101 efficacy to be at least as good as the current treatments, is targeting the number of patients hitting under that target of 500, and estimates the target population at about 1.1 million across U.S. and EU5, or EU4 plus U.K.

  • Strategic Transformation Toward In Vivo Gene EditingCellectis has transformed into an in vivo gene editing company focused initially on severe dyslipidemias, with HEAL-101 and HEAL-201 designed as single-injection therapies with the potential for long-lasting effects.
  • HEAL-101 Demonstrated Efficient and Precise APOC3 EditingIn a human hepatic cell line, HEAL-101 achieved approximately 90% mean APOC3 editing, with minimal indels, no detectable DNA double-strand breaks at the target site, no detectable editing at the top putative off-target sites, and a marked reduction in APOC3 protein secretion.
  • HEAL-101 Reduced Triglycerides in Preclinical Disease ModelsIn a normal lipidemic humanized-liver mouse model, a single intravenous dose produced approximately 65% mean APOC3 editing, reaching up to 70%, with lower circulating APOC3 and triglycerides and no significant increase in ALT versus untreated controls. In a hypertriglyceridemic human APOC3 transgenic mouse model, HEAL-101 reduced APOC3 levels by 67% and triglycerides by 76%.
  • Liver-Restricted HEAL-101 Activity and Reassuring Safety FindingsIn the hypertriglyceridemic mouse model, editing was detected in the liver with no significant editing detected in the other tissues analyzed. Management also described liver toxicity data from mouse and non-human primate studies as very reassuring.
  • HEAL-101 China Trial Remains on TrackThe investigator-initiated HEAL-101 trial in China remains on track, with initiation expected after dose modeling and preparation activities. Preliminary clinical data are expected in the second half of 2027, and management anticipates that the starting dose will be effective while still allowing dose escalation.
  • HEAL-101 Target Selection Supported by Market ResearchManagement selected APOC3 over ANGPTL3 for severe hypertriglyceridemia based on market research indicating that APOC3 was viewed as superior for triglyceride reduction. The company stated that its goal is to address the risk of pancreatitis through a highly focused triglyceride-lowering therapy.
  • HEAL-101 Expected to Compete With Existing TherapiesManagement stated that it expects HEAL-101 efficacy to be at least as good as current treatments and emphasized optimizing the proportion of patients reaching triglyceride levels below 500, a threshold it described as critical for risks associated with severe hypertriglyceridemia.
  • HEAL-201 Produced Greater Than 90% PCSK9 SuppressionIn vitro, HEAL-201 achieved mean on-site epigenetic editing above 90% in human hepatic cell lines, with no off-site changes detected in gene or protein expression. In a humanized-liver mouse model, it reduced mean plasma PCSK9 levels by more than 90%.
  • HEAL-201 Phase I Preparation and MilestoneCellectis is preparing HEAL-201 for a planned Phase I study, with preliminary clinical data expected in the first half of 2028.
  • Potentially Broad Commercial Opportunity for HEAL-101Management estimated the target population for HEAL-101 at approximately 1.1 million patients across the U.S. and EU5, or EU4 plus the U.K. The company said market research supports positioning the product as a potentially best-in-class therapy in an established severe hypertriglyceridemia market.
  • Potential Pricing and Gross-Margin OpportunityManagement stated that demonstrating durability over multiple years could support higher pricing relative to current severe hypertriglyceridemia therapies and noted that mRNA formulated in LNPs has an extremely low cost of goods, creating what it described as tremendous gross-margin potential.
  • LNP Delivery System Has Prior Clinical ExperienceThe LNP delivery system being used for HEAL-101 has been used clinically by the company's biotech partner for liver transduction with RNA and was described as having a very good safety profile and very high efficiency. Existing clinical experience and non-human primate data are supporting dose modeling and potentially a higher starting dose.
  • Cash Runway Extends Into the Second Half of 2028Once the realignment is fully implemented as planned, management expects a cash runway into the second half of 2028, extending beyond the expected HEAL-101 clinical data in the second half of 2027 and HEAL-201 clinical data in the first half of 2028.
  • Improved Net Financial ResultFor the nine months ended September 30, 2026, Cellectis reported a consolidated net gain of $5.2 million versus a net financial loss of $25.6 million in the prior-year period, a $30.8 million improvement. The change reflected a $10.8 million increase in financial income and a $20.0 million decrease in financial expenses, including lower foreign exchange losses and gains from fair value measurements.
  • Partnerships Remain a Source of ValueManagement said its partnerships with AstraZeneca, Servier, Allogene, and Iovance remain an important source of value for Cellectis.
  • Future Spending Focused on the New PipelineFollowing the operating-model realignment, Cellectis expects cash spending to be primarily focused on advancing HEAL-101, HEAL-201, and potential new product candidates, while funding one-off restructuring costs.

DE:ZVA Earnings History

DE:ZVA earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 04, 20272026 (Q4)-0.23--0.22――
Nov 13, 20262026 (Q3)-0.16-0.550.01-6244.44% (-0.56)
Aug 06, 20262026 (Q2)-0.23-0.19-0.218.65% (+0.02)
May 11, 20262026 (Q1)-0.22-0.15-0.164.97% (+0.01)
Mar 19, 20262025 (Q4)-0.17-0.22-0.16-42.31% (-0.07)
Nov 07, 20252025 (Q3)-0.200.01-0.21104.27% (+0.22)
Aug 04, 20252025 (Q2)-0.19-0.21-0.2618.75% (+0.05)
May 12, 20252025 (Q1)-0.14-0.160.07-317.57% (-0.23)
Mar 13, 20252024 (Q4)-0.17-0.16-0.673.96% (+0.44)
Nov 04, 20242024 (Q3)-0.22-0.21-0.2927.24% (+0.08)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed